Contact us  |  Disclaimer  |  Sitemap
  • ABOUT US
  • MISSION & VALUES
  • BUSINESS STRATEGY
  • OUR HISTORY
  • MANAGEMENT
  • BOARD OF DIRECTORS
  • SCIENTIFIC ADVISORY BOARDS
  • CORPORATE GOVERNANCE
    • GOVERNANCE DOCUMENTS
    • RISK MANAGEMENT
  • CAREERS
ABOUT US
  • PRODUCTS
  • LCP-Tacro™
    • Why immunosuppression?
    • About organ transplantations
    • MARKET OVERVIEW
    • Product programs
    • Development strategy and status
    • Commercial strategy
  • Cardiovascular
PRODUCTS
  • TECHNOLOGY
  • MELTDOSE® TECHNOLOGY PLATFORM
  • INTELLECTUAL PROPERTY RIGHTS
TECHNOLOGY
  • INVESTOR RELATIONS
  • RELEASES
  • DOWNLOAD CENTER
  • CALENDAR
  • FINANCIAL INFORMATION
    • OUTLOOK
  • STOCK INFORMATION
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ORDER DEPTH AND LATEST TRADES
    • DIVIDEND HISTORY
    • ANALYST COVERAGE
  • General Meetings
INVESTOR
  • MEDIA
MEDIA
  • INVESTOR RELATIONS
  • RELEASES
  • DOWNLOAD CENTER
  • CALENDAR
  • FINANCIAL INFORMATION
    • OUTLOOK
  • STOCK INFORMATION
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ORDER DEPTH AND LATEST TRADES
    • DIVIDEND HISTORY
    • ANALYST COVERAGE
  • General Meetings

Financial Highlights

STOCK INFORMATION


LATEST RELEASES

May 30, 2013
Veloxis Pharmaceuticals A/S — annulment of warrants and registration of new Articles of Association pursuant thereto

May 21, 2013
European Medicines Agency (EMA) Accepts Veloxis' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patients

May 20, 2013
Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors

May 15, 2013
Veloxis Pharmaceuticals announces financial results for the first three months of 2013



Shareholder Briefcase

email alerts

download library

snapshot

mobile investor

RSS News Feeds

Print Page

Email Page

Share this on: Close window
delicious Delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter
What is this?

Veloxis Pharmaceuticals A/S | Bøge Allé 5, 2th | DK-2970 Hørsholm | Tel. +4570333300 | CVR-no. 26 52 77 67 | info@veloxis.com